1. Inicio
  2. Proyectos y Estudios
  3. A Phase IIIB study to evaluate the use of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line treatment in Patients with Newly Diagnosed pMMR Advanced or Recurrent Endometrial Cancer in Spain.

A Phase IIIB study to evaluate the use of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line treatment in Patients with Newly Diagnosed pMMR Advanced or Recurrent Endometrial Cancer in Spain.

Datos básicos

ENSAYO CLÍNICO D9311L00001 HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE Año de incio: 2025

Documentos

  • No hay documentos

Participantes

Ver todos los Investigadores

Grupos

Financiadores - Promotores

ASTRAZENECA FARMACÉUTICA SPAIN, S.A.

Compartir